{"symbol":"BMY","fiscalQuarter":"Q1-2026","reportDate":"2026-04-30","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q1-2026","estimates":{"consensusEps":1.4187,"consensusRevenue":10910.94,"epsLow":1.23,"epsHigh":1.53,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for serious diseases. As a key player in the health care sector, its performance can significantly impact investor sentiment, especially given ongoing trends in biotechnology and personalized medicine.","keyMetrics":[{"name":"EPS","why":"Earnings per share (EPS) is a crucial indicator of the company's profitability and financial health.","consensus":"$1.42"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and market demand for its products.","consensus":"$10.9B"}],"lastQuarterRecap":{"summary":"In Q4 2025, Bristol-Myers Squibb reported an EPS of $1.26, surpassing expectations by 9.28%. The stock reacted positively, gaining 3.30% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Bristol-Myers Squibb to report solid earnings this quarter, with a consensus EPS of $1.42 and revenue of $10.9 billion. The company has a history of exceeding EPS estimates, which could lead to positive market reactions.","bullCase":"If the company beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a significant stock price increase.","bearCase":"Conversely, if the company misses EPS expectations or shows declining revenue, it could raise concerns about its growth prospects and negatively impact the stock."},"optionsSignal":{"impliedMove":"4.5%","context":"The options market is pricing in a potential move of about 4.5% in either direction following the earnings report, indicating some uncertainty among investors."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+9.28%","reaction":"+3.30%"},{"quarter":"Q3-2025","epsSurprise":"+10.14%","reaction":"+7.09%"},{"quarter":"Q2-2025","epsSurprise":"-12.63%","reaction":"-5.81%"},{"quarter":"Q1-2025","epsSurprise":"+19.52%","reaction":"+0.33%"},{"quarter":"Q4-2024","epsSurprise":"+14.15%","reaction":"-3.84%"},{"quarter":"Q3-2024","epsSurprise":"+21.05%","reaction":"+5.91%"},{"quarter":"Q2-2024","epsSurprise":"+26.53%","reaction":"+11.44%"},{"quarter":"Q1-2024","epsSurprise":"-387.21%","reaction":"-8.51%"}],"pivotalQuestions":[{"question":"Will the EPS exceed $1.42, indicating continued strong performance?","whyItMatters":"A beat on EPS could reinforce investor confidence and lead to a positive stock reaction."},{"question":"What are the revenue figures, and do they align with the $10.9 billion consensus?","whyItMatters":"Revenue performance is critical for assessing the company's growth trajectory and market demand."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.50 or higher would confirm the bull case and suggest strong underlying business performance.","bearTrigger":"An EPS below $1.30 would support the bear case and raise concerns about the company's growth prospects.","context":"The market is focused on both EPS and revenue growth as indicators of Bristol-Myers Squibb's future performance."},"scenarioPlaybook":{"beatAndRaise":"If Bristol-Myers Squibb beats expectations, history suggests a positive stock reaction of around +4.04%, confirming strong demand for its products.","inLineCautious":"If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.","miss":"A miss on EPS could lead to a decline in stock price, with historical patterns indicating an average drop of -7.16%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options pricing cheap in Health Care","sampleSize":30,"fadeRate":"7 of 23 (30%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days \u2014 this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Bristol-Myers Squibb to exceed EPS expectations, given its recent history of strong performance.","supportingPoints":["Bristol-Myers has a 75% EPS beat rate over the last eight quarters, indicating a strong likelihood of exceeding expectations.","The average 1-day move when they beat is +4.04%, suggesting that positive surprises have historically led to significant stock gains."],"riskToConsensus":"If the company reports an EPS below $1.30, it could invalidate the bullish sentiment."},"whatToListenFor":["Any updates on new drug approvals or pipeline advancements.","Insights into market demand for key products like Opdivo and Eliquis.","Management's commentary on cost management and operational efficiencies.","Guidance on future revenue growth and market expansion strategies.","Responses to questions about competitive pressures in the pharmaceutical industry."],"metaDescription":"Bristol-Myers Squibb (BMY) reports Q1 2026 earnings April 30. Analysts expect $1.42 EPS on $10.9B revenue. Here's what to watch."},"postBrief":{"headline":"Bristol-Myers Squibb Beats on EPS, Stock Up 5.21%","keyNumbers":[{"metric":"EPS","actual":"$1.58","expected":"$1.42","surprise":"+9.65%"},{"metric":"Revenue","actual":"N/A","expected":"$10.9B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based on numerical results only."},"guidanceChanges":{"summary":"No guidance data is available.","changes":[]},"whatItMeans":"Bristol-Myers Squibb reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 5.21%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data could lead to cautious sentiment moving forward.","metaDescription":"Bristol-Myers Squibb (BMY) Q1 2026 earnings: EPS beat by 9.65%, revenue not available. Stock up 5.21%. Full breakdown."}}